Report Detail

Pharma & Healthcare Global and China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, Status and Forecast 2021-2027

  • RnM4342145
  • |
  • 03 September, 2021
  • |
  • Global
  • |
  • Pages: NA
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Market Analysis by Type
      • 1.2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
      • 1.2.2 Single-stranded AAV (ssAAV)
      • 1.2.3 Self-complementary AAV (scAAV)
    • 1.3 Market by Application
      • 1.3.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Application: 2016 VS 2021 VS 2027
      • 1.3.2 Hemophilia
      • 1.3.3 Ophthalmology
      • 1.3.4 Lysosomal Storage Disorders
      • 1.3.5 Neurological Disorders
      • 1.3.6 Others
    • 1.4 Study Objectives
    • 1.5 Years Considered

    2 Global Growth Trends

    • 2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Perspective (2016-2027)
    • 2.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Growth Trends by Regions
      • 2.2.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Regions: 2016 VS 2021 VS 2027
      • 2.2.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Historic Market Share by Regions (2016-2021)
      • 2.2.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Regions (2022-2027)
    • 2.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industry Dynamic
      • 2.3.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Trends
      • 2.3.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Drivers
      • 2.3.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Challenges
      • 2.3.4 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Restraints

    3 Competition Landscape by Key Players

    • 3.1 Global Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players by Revenue
      • 3.1.1 Global Top Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players by Revenue (2016-2021)
      • 3.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Players (2016-2021)
    • 3.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    • 3.3 Players Covered: Ranking by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue
    • 3.4 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Concentration Ratio
      • 3.4.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Concentration Ratio (CR5 and HHI)
      • 3.4.2 Global Top 10 and Top 5 Companies by Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue in 2020
    • 3.5 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Key Players Head office and Area Served
    • 3.6 Key Players Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Solution and Service
    • 3.7 Date of Enter into Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market
    • 3.8 Mergers & Acquisitions, Expansion Plans

    4 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Breakdown Data by Type

    • 4.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Historic Market Size by Type (2016-2021)
    • 4.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Type (2022-2027)

    5 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Breakdown Data by Application

    • 5.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Historic Market Size by Application (2016-2021)
    • 5.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Application (2022-2027)

    6 North America

    • 6.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2016-2027)
    • 6.2 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type
      • 6.2.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2016-2021)
      • 6.2.2 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2022-2027)
      • 6.2.3 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2016-2027)
    • 6.3 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application
      • 6.3.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2016-2021)
      • 6.3.2 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2022-2027)
      • 6.3.3 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2016-2027)
    • 6.4 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country
      • 6.4.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2016-2021)
      • 6.4.2 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2022-2027)
      • 6.4.3 United States
      • 6.4.4 Canada

    7 Europe

    • 7.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2016-2027)
    • 7.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type
      • 7.2.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2016-2021)
      • 7.2.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2022-2027)
      • 7.2.3 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2016-2027)
    • 7.3 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application
      • 7.3.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2016-2021)
      • 7.3.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2022-2027)
      • 7.3.3 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2016-2027)
    • 7.4 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country
      • 7.4.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2016-2021)
      • 7.4.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2022-2027)
      • 7.4.3 Germany
      • 7.4.4 France
      • 7.4.5 U.K.
      • 7.4.6 Italy
      • 7.4.7 Russia
      • 7.4.8 Nordic

    8 Asia-Pacific

    • 8.1 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2016-2027)
    • 8.2 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type
      • 8.2.1 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2016-2021)
      • 8.2.2 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2022-2027)
      • 8.2.3 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2016-2027)
    • 8.3 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application
      • 8.3.1 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2016-2021)
      • 8.3.2 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2022-2027)
      • 8.3.3 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2016-2027)
    • 8.4 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region
      • 8.4.1 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2016-2021)
      • 8.4.2 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2022-2027)
      • 8.4.3 China
      • 8.4.4 Japan
      • 8.4.5 South Korea
      • 8.4.6 Southeast Asia
      • 8.4.7 India
      • 8.4.8 Australia

    9 Latin America

    • 9.1 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2016-2027)
    • 9.2 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type
      • 9.2.1 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2016-2021)
      • 9.2.2 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2022-2027)
      • 9.2.3 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2016-2027)
    • 9.3 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application
      • 9.3.1 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2016-2021)
      • 9.3.2 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2022-2027)
      • 9.3.3 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2016-2027)
    • 9.4 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country
      • 9.4.1 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2016-2021)
      • 9.4.2 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2022-2027)
      • 9.4.3 Mexico
      • 9.4.4 Brazil

    10 Middle East & Africa

    • 10.1 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2016-2027)
    • 10.2 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type
      • 10.2.1 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2016-2021)
      • 10.2.2 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2022-2027)
      • 10.2.3 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2016-2027)
    • 10.3 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application
      • 10.3.1 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2016-2021)
      • 10.3.2 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2022-2027)
      • 10.3.3 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2016-2027)
    • 10.4 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country
      • 10.4.1 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2016-2021)
      • 10.4.2 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2022-2027)
      • 10.4.3 Turkey
      • 10.4.4 Saudi Arabia
      • 10.4.5 UAE

    11 Key Players Profiles

    • 11.1 BioMarin Pharmaceutical
      • 11.1.1 BioMarin Pharmaceutical Company Details
      • 11.1.2 BioMarin Pharmaceutical Business Overview
      • 11.1.3 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
      • 11.1.4 BioMarin Pharmaceutical Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2016-2021)
      • 11.1.5 BioMarin Pharmaceutical Recent Development
    • 11.2 Sangamo Therapeutics
      • 11.2.1 Sangamo Therapeutics Company Details
      • 11.2.2 Sangamo Therapeutics Business Overview
      • 11.2.3 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
      • 11.2.4 Sangamo Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2016-2021)
      • 11.2.5 Sangamo Therapeutics Recent Development
    • 11.3 Amicus Therapeutics
      • 11.3.1 Amicus Therapeutics Company Details
      • 11.3.2 Amicus Therapeutics Business Overview
      • 11.3.3 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
      • 11.3.4 Amicus Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2016-2021)
      • 11.3.5 Amicus Therapeutics Recent Development
    • 11.4 Roche
      • 11.4.1 Roche Company Details
      • 11.4.2 Roche Business Overview
      • 11.4.3 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
      • 11.4.4 Roche Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2016-2021)
      • 11.4.5 Roche Recent Development
    • 11.5 Pfizer
      • 11.5.1 Pfizer Company Details
      • 11.5.2 Pfizer Business Overview
      • 11.5.3 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
      • 11.5.4 Pfizer Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2016-2021)
      • 11.5.5 Pfizer Recent Development
    • 11.6 NightstaRx
      • 11.6.1 NightstaRx Company Details
      • 11.6.2 NightstaRx Business Overview
      • 11.6.3 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
      • 11.6.4 NightstaRx Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2016-2021)
      • 11.6.5 NightstaRx Recent Development
    • 11.7 MeiraGTx
      • 11.7.1 MeiraGTx Company Details
      • 11.7.2 MeiraGTx Business Overview
      • 11.7.3 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
      • 11.7.4 MeiraGTx Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2016-2021)
      • 11.7.5 MeiraGTx Recent Development
    • 11.8 Sarepta Therapeutics
      • 11.8.1 Sarepta Therapeutics Company Details
      • 11.8.2 Sarepta Therapeutics Business Overview
      • 11.8.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
      • 11.8.4 Sarepta Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2016-2021)
      • 11.8.5 Sarepta Therapeutics Recent Development
    • 11.9 Neurocrine Biosciences
      • 11.9.1 Neurocrine Biosciences Company Details
      • 11.9.2 Neurocrine Biosciences Business Overview
      • 11.9.3 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
      • 11.9.4 Neurocrine Biosciences Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2016-2021)
      • 11.9.5 Neurocrine Biosciences Recent Development
    • 11.10 Voyager Therapeutics
      • 11.10.1 Voyager Therapeutics Company Details
      • 11.10.2 Voyager Therapeutics Business Overview
      • 11.10.3 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
      • 11.10.4 Voyager Therapeutics Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2016-2021)
      • 11.10.5 Voyager Therapeutics Recent Development
    • 11.11 Asklepios Biopharmaceutical
      • 11.11.1 Asklepios Biopharmaceutical Company Details
      • 11.11.2 Asklepios Biopharmaceutical Business Overview
      • 11.11.3 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
      • 11.11.4 Asklepios Biopharmaceutical Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Business (2016-2021)
      • 11.11.5 Asklepios Biopharmaceutical Recent Development

    12 Analyst's Viewpoints/Conclusions

      13 Appendix

      • 13.1 Research Methodology
        • 13.1.1 Methodology/Research Approach
        • 13.1.2 Data Source
      • 13.2 Disclaimer

      AAV is transformed from a naturally occurring virus into a delivery mechanism for gene therapy. The viral DNA is replaced with new DNA, and it becomes a precisely coded vector and is no longer considered a virus, as most of the viral components have been replaced. The AAV Vector-Based Gene Therapy market size is anticipated to shoot up exponentially attributing to an increase in the approval of a growing number of gene therapies and readily adoption on approval, ability to treat a broad array of conditions, increasing prevalence of diseases, convenient one-time dosing approach and curative treatment options.
      Market Snapshot
      A recently published report by QY Research, titled “Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, Status and Forecast 2021-2027” gives an overview of the overall Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market. This section sheds light on key impact-rendering drivers and constraints that are impacting the growth. It permits users to understand the different shortcomings and how they may hamper the development afterward. This segment is considered to be one of the most crucial segments of the report as it helps readers comprehend the impact of various macro and microeconomic factors on development. The role of various sectors, including small-scale and large-scale, in the expansion has also been discussed in the report. Additionally, the industry experts have put forth the current trends and prospects, which are likely to aid the growth in the upcoming years.
      The global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market size is projected to reach US$ million by 2027, from US$ million in 2020, at a CAGR of % during 2021-2027.
      Impact of Covid-19 Outbreak
      This section of the report has explored the overall status of the Covid scenario and has offered valuable insights into the changes in supply chain disruption, fluctuations in demand, etc. The analysts have also focused on the key measures that the companies are opting to withstand the harsh scenario.
      Segmental Analysis
      The report has been segmented into product and application segments. The researchers have documented all the products present today in the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market. They have also shed light on the new product innovations and launches by the key players. In the segmental analysis, the analysts have provided revenue forecast figures based on type and application for the period 2016-2027. They have also discussed about the growth rate and potential of each segment for the period 2016-2027.
      Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Breakdown Data by Type
      Single-stranded AAV (ssAAV)
      Self-complementary AAV (scAAV)
      Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Breakdown Data by Application
      Hemophilia
      Ophthalmology
      Lysosomal Storage Disorders
      Neurological Disorders
      Others
      Regional Analysis
      The significant regions that are studied in the research report encompass North America, Europe, Asia Pacific, Central and South America, and the Middle East and Africa. In this section of the report, the specialists have explored various areas that are contributing to the development and can present lucrative growth prospects for the manufacturers in the forthcoming years. The report also provides region-wise and country-wise sales and revenue forecast data for the period 2021-2027.
      Competitive Landscape
      This segment focuses on the key players operating in the industry. It underlines all the current and future activities by the prominent manufacturers. By understanding various initiatives being taken up by different players, readers will gain the ability to settle on correct business choices. The authors of the report have provided accurate revenue figures of the companies for the period 2016-2021. The clients are sure to gain the upper hand once they get hold of this report. Key players studied in the research report include:
      BioMarin Pharmaceutical
      Sangamo Therapeutics
      Amicus Therapeutics
      Roche
      Pfizer
      NightstaRx
      MeiraGTx
      Sarepta Therapeutics
      Neurocrine Biosciences
      Voyager Therapeutics
      Asklepios Biopharmaceutical


      Summary:
      Get latest Market Research Reports on Adeno-Associated Virus (AAV) Vector-Based Gene Therapy. Industry analysis & Market Report on Adeno-Associated Virus (AAV) Vector-Based Gene Therapy is a syndicated market report, published as Global and China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size, Status and Forecast 2021-2027. It is complete Research Study and Industry Analysis of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,500.00
      $7,000.00
      2,548.00
      5,096.00
      2,978.50
      5,957.00
      384,930.00
      769,860.00
      257,600.00
      515,200.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report